Biocon announced that USFDA concluded a pre-approval inspection of Biocon's insulin drug substance manufacturing facility triggered by a New Drug Application submitted by the company's insulin AP/ customer. The inspection at the Bengaluru facility took place between 25 February - 5 March 2019, resulting in a Form 483 with six observations
0 thoughts on “Biocon announces conclusion of USFDA preapproval inspection of its insulin manufacturing facility at Bangalore”